Drug intelligence / Profile preview

caffeine + bupropion + rosiglitazone + omeprazole + midazolam + bilirubin

Development stage
Unknown
Lead developer
GSK
Modality
Small Molecules
Administration
Oral, Intravenous, Intramuscular, Intranasal, Buccal
01

Overview

This is a combination of six distinct compounds: - **Caffeine** is a central nervous system stimulant commonly found in coffee and other beverages. - **Bupropion** is an atypical antidepressant and smoking cessation aid that acts as a norepinephrine-dopamine reuptake inhibitor. - **Rosiglitazone** is an antidiabetic agent in the thiazolidinedione class that improves insulin sensitivity by acting as a peroxisome proliferator-activated receptor gamma (PPARγ) agonist. - **Omeprazole** is a proton pump inhibitor used to reduce stomach acid production by irreversibly inhibiting the H+/K+-ATPase enzyme system on gastric parietal cells[1][2][3][4][5][8]. - **Midazolam** is a benzodiazepine used for sedation and anesthesia; it enhances the effect of GABA at the GABAA receptor[6]. - **Bilirubin** is not typically considered a drug but rather an endogenous breakdown product of heme metabolism; it can be measured clinically as an indicator of liver function. This combination does not represent any known marketed pharmaceutical product or therapy. Each component has distinct mechanisms and indications.

Other names
caffeinebupropionrosiglitazoneomeprazolemidazolambilirubin
02

Targets

GABRR (GABA-A receptor subunit rho)ATP4A (Potassium–transporting ATPase alpha chain 1)ADOR (Adenosine receptors)PPARG (Peroxisome proliferator-activated receptor gamma)DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)

Beyond the preview

Go deeper on caffeine + bupropion + rosiglitazone + omeprazole + midazolam + bilirubin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on caffeine + bupropion + rosiglitazone + omeprazole + midazolam + bilirubin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call